



Attorney Docket No. 1830.1023

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re l	atent Ap	plica	tion of:	
Kazul	niro OBAI	E et a	ıl.	
Applic	cation No	.: 10	/580,863	Group Art Unit:
Confi	mation N	10.		·
Filed:	May 26,	2006	3	Examiner:
For:	NONR	EDUC	CING B-GLUCAN DERIVATIVE	
			INFORMATION DISCLOS	SURE STATEMENT
PO B	nissioner ox 1450 ndria, VA			
subje	led certai ct U.S. pa	in info atent	ormation which the Examiner ma	ovisions of 37 CFR § 1.56, there is hereby by consider material to the examination of the the Examiner make this information of record oject application.
1.	Enclos	ures a	accompanying this Information [Disclosure Statement are:
	1a. 1b.		Form PTO-1449. Copy(ies) of IDS citation(s), excapplication publications.	cept for U.S. Patents and U.S. Patent
	1c.	\boxtimes	• •	nmunication(s) from a foreign Patent Office
	1d.		English language translation (c	omplete, Abstract or relevant portion(s)) ge publications as indicated on the attached
	1e.			References (ATTACHMENT 1(e), hereto) for of non-English publications.
	1f. 1g.	\square	List of Copending Applications	
2. 🛭	This	Inforr	mation Disclosure Statement is f	
	_	_	(Check either Item 2	•
	2a. 2b.		Within three months of the filing Within three months of the date § 1.491 in an international appl	e of entry of the national stage as set forth in
	2c. 2d.		Before the mailing of a first Offi	ce Action on the merits; or ce Action after the filing of a Request for

Serial No.: 10/580,863

3.	specified Action un	mation Disclosure Statement is filed under 37 CFR § 1.97(c) after the period in paragraph 2 above but before the mailing date of any of a Final Office der § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise osecution in the application, AND
		(Check either Item 3a or 3b; Item 3b to be checked if any reference known for more than 3 months)
	3a.	The § 1.97(e) Statement in Item 5 below is applicable; OR The \$180.00 fee set forth in 37 CFR § 1.17(p) is: enclosed.
	,	to be charged to Deposit Account No. 19-3935.
4.		mation Disclosure Statement is filed under 37 CFR § 1.97(d) after the period in paragraph 3 above, but on or before payment of the Issue Fee, AND
	4a.	The § 1.97(e) Statement in Item 5 below is applicable; AND The \$180.00 fee set forth in 37 CFR § 1.17(p) is: enclosed.
		to be charged to Deposit Account No. 19-3935.
5.	Statemen	t under § 1.97(e) (applicable if Item 3a or Item 4a is checked) (Check either Item 5a or 5b)
	5a. 🗌	In accordance with 37 CFR § 1.97(e)(1), it is stated that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	5b.	In accordance with 37 CFR § 1.97(e)(2), it is stated that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known by any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
6.	This is a (1.53(b).	continuation/divisional/continuation-in-part application under 37 CFR §
		(Check appropriate Items 6a and/or 6b)
	6a. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR § 1.98(d).
	6b. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were not previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, are provided herewith.

Serial No.: 10/580,863

7.		This is a	Request for Continued Examination under 37 CFR § 1.114.
			(Check either Item 7a or 7b)
		7a.	The Issue Fee has not been paid. A Petition to Withdraw from issue under 37 CFR § 1.313(c) is filed concurrently herewith or has been granted. A Request for Continued Examination under 37 CFR § 1.114, after payment of the Issue Fee, is proper in accordance with 37 CFR § 1.114(a), respectively.
8.		This is a	Supplemental Information Disclosure Statement.
			(Check either Item 8a or 8b)
		8a. 🗌	This Supplemental Information Disclosure Statement under 37 CFR § 1.97(f) supplements the Information Disclosure Statement filed on A bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental IDS can
		8b. 🗌	be considered as if properly filed on This Supplemental Information Disclosure Statement is timely filed within one (1) month of the Notice under 37 CFR §§ 1.97 and 1.98, mailed
9.			nce with 37 CFR § 1.98, a concise explanation of what is presently it to be the relevance of each non-English language publication is:
			(Check appropriate Items 9a, 9b, 9c and/or 9d)
		9a.	satisfied for the non-English language publication(s) cited on the enclosed "English language version of the search report or action which indicates the degree of relevance found by the foreign office". (See MPEP § 609, Minimum Requirements for an Information Disclosure Statement, Part A(3): Concise Explanation of Relevance, 8th Ed., Rev. 2) set forth in the application.
		9c.	satisfied for the non-English language publication(s) indicated on the attached Form PTO-1449 as having an English language translation (complete or relevant portion(s)) attached thereto.
		9d. 🗌	enclosed as Attachment 1(e), hereto.
10.	be se	e, material earch repo	on is made that the information cited in this Statement is, or is considered to to patentability nor a representation that a search has been made (other than rt(s) from a counterpart foreign application or a PCT International Search (bmitted herewith). 37 CFR §§ 1.97(g) and (h).

Serial No.: 10/580,863

11. The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement to Deposit Account No. 19-3935.

Respectfully submitted,

STAAS & HALSEY LLP

Registration No. 34,257

Dated: // 2007 1201 New Yark Ave., N.W., 7th Floor

Washington, D.C. 20005 Telephone: (202) 434-1500 Facsimile: (202) 434-1501

©2005 Staas & Halsey LLP



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO. 1830.1023

Sheet 1 of 1 APPLICATION NO.

1830.1023 10/580,863 FIRST NAMED INVENTOR

Kazuhiro OBAE et al.

FILING DATE

May 26, 2006

GROUP ART UNIT

(Use several sheets if necessary)

INFORMATION DISCLOSURE STATEMENT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA	2003/0100749	05/29/2003	Withers et al.			
	AB						
	AC						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	TRANSLA YES	ATION NO	ABSTRACT
AD	WO 01/33973	05/17/2001	WIPO			
AE	0 470 331	02/12/1992	Europe			
AF						
AG						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
АН	Shiro Kobayashi et al., "Chemical synthesis of cellulose and cello- oligomers using a hydrolysis enzyme as a catalyst", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, BUTTERWORTH & CO., GUILDFORD, GREAT BRITAIN, Vol. 17, No. 6, 1995, Pgs. 373-379.				
AI	K. Bhat et al., "Study of the mode of action and site specificity of the endo-(1-4)-beta-D-glucanases of the fungus Penicillium pinophilum with normal, 1-3H-labelled, reduced and chromogenic cello-oligosaccharides", BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GREAT BRITAIN, Vol. 266, No. 2, March 1, 1990, Pgs. 371-378.				

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not cita	
citation if not in conformance and not considered. Include copy of	of this form with next communication to applicant.



ATTACHMENT 1(g)

LIST	OF	ADDI	ΓΙΟΝΑL	SUBMI'	TTED
		DOC	CUMEN'	TS	

ATTORNEY DOCKET NO.	APPLICATION NO.
1830.1023	10/580,863
FIRST NAMED INVENTOR	
Kazuhiro OBAE et al.	
FILING DATE	GROUP ART UNIT
May 26, 2006	

The following document(s) is/are listed in accordance with the duty of disclosure provisions of 37 CFR § 1.56, so that the Examiner may consider same should he deem any thereof to be material to examination of the subject application.

It is requested that the Examiner acknowledge his consideration of document(s) below-listed by initialling same in the space provided adjacent each such application and that the Examiner sign and date this form at the bottom thereof to confirm such consideration having been given.

This submission in no way represents an admission that any of the information listed herein constitutes prior art with respect to the subject application; and unless and until such prior art status is established, this submission is not a request that the information presented herein be printed on the face of any patent issuing from the subject application in which this information is being filed.

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSL YES	ATION NO
AC							
AD							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	AE	Supplementary European Search Report, mailed March 26, 2007, and issued in corresponding European Patent Application No. 04819431.0-2115			

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	